In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $15.87 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

Akeso and Summit Therapeutics' ivonescimab showed strong efficacy against Merck's Keytruda in a phase 3 trial in China. The ...